177 related articles for article (PubMed ID: 35965552)
21. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
22. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Values of Baseline
Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
[TBL] [Abstract][Full Text] [Related]
24. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
Zhang YY; Song L; Zhao MX; Hu K
Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
[TBL] [Abstract][Full Text] [Related]
25. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
Alongi P; Caobelli F; Gentile R; Stefano A; Russo G; Albano D; Baldari S; Gilardi MC; Midiri M
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):224-233. PubMed ID: 27565154
[TBL] [Abstract][Full Text] [Related]
26. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
[TBL] [Abstract][Full Text] [Related]
27. Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer.
Li Y; Liu C; Wang B; Hu X; Gong C; Zhao Y; Xie Y; Zhang Y; Song S; Yang Z; Wang B
Int J Gen Med; 2021; 14():1797-1809. PubMed ID: 34007206
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.
Xie M; Zhai W; Cheng S; Zhang H; Xie Y; He W
Hematology; 2016 Mar; 21(2):99-105. PubMed ID: 26183456
[TBL] [Abstract][Full Text] [Related]
29. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
31. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
32. [Value of
Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
[TBL] [Abstract][Full Text] [Related]
34. Imaging characteristics and prognostic values of hepatic epithelioid hemangioendothelioma on
Wang W; Liu G; Hu P; Pang L; Gu T; Yu H; Luo R; Yang X; Shi H
Clin Exp Med; 2020 Nov; 20(4):557-567. PubMed ID: 32797371
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic Value of Maximum Standard Uptake on Pretreatment ¹⁸F-FDG PET/CT Scan in Newly Diagnosed Follicular Lymphoma].
Ding CY; Sun J; Li TN; Xu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1331-5. PubMed ID: 26524032
[TBL] [Abstract][Full Text] [Related]
36. Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
Cottereau AS; Rebaud L; Trotman J; Feugier P; Nastoupil LJ; Bachy E; Flinn IW; Haioun C; Ysebaert L; Bartlett NL; Tilly H; Casasnovas O; Ricci R; Portugues C; Buvat I; Meignan M; Morschhauser F
Ann Oncol; 2024 Jan; 35(1):130-137. PubMed ID: 37898239
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
38. The Use of
Hlongwa KN; Mokoala KMG; Matsena-Zingoni Z; Vorster M; Sathekge MM
Diagnostics (Basel); 2022 Feb; 12(3):. PubMed ID: 35328148
[TBL] [Abstract][Full Text] [Related]
39. Nomograms based on SUVmax of
Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
